Peginesatide as a new approach for treating anemia of CKD patient: is it like a falling star?

Figures & data

Figure 1. Percentage of patients developing antibodies against peginesatide [3,4], recombinant human (rHu) insulin [7], interferon α [8] and β [9].

Fineberg SE, Galloway JA, Fineberg NS, et al. Immunogenicity of recombinant DNA human insulin. Diabetologia 1983;25:465-9

 PubMed Web of Science ®Google Scholar

Matsuda F, Torii Y, Enomoto H, et al. Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis C. J Viral Hepat 2012;19:694-703

 PubMedGoogle Scholar

Jungedal R, Lundkvist M, Engdahl E, et al. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice. Mult Scler 2012;18:1775-81

 PubMed Web of Science ®Google Scholar